Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: A Cochrane systematic review

BMJ Open

Volumn 4, Issue 7, 2014, Pages

  Peinemann, Frank ^a   Labeit, Alexander Michael ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULTHOOD; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; CHILDHOOD; COMPARATIVE EFFECTIVENESS; DRUG TREATMENT FAILURE; EVALUATION STUDY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LIVING DONOR; META ANALYSIS; METHODOLOGY; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; QUALITY OF LIFE; REVIEW; SIBLING RELATION; SYSTEMATIC REVIEW; ADOLESCENT; ADVERSE EFFECTS; ANEMIA, APLASTIC; CHILD; COMPARATIVE STUDY; DONOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFANT; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; SIBLING; TREATMENT OUTCOME; YOUNG ADULT;

IMMUNOSUPPRESSIVE AGENT;

ADOLESCENT; ANEMIA, APLASTIC; CHILD; CHILD, PRESCHOOL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; SEVERITY OF ILLNESS INDEX; SIBLINGS; TISSUE DONORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904502471     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-005039     Document Type: Review

References (33)

1. Genetic and Rare Diseases Information Center (GARD). Aplastic anemia. Bethesda: The Office of Rare Diseases Research (ORDR) and the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), 2013.
2. Kaufman DW, Kelly JP, Issaragrisil S, et al. Relative incidence of agranulocytosis and aplastic anemia. Am J Hematol 2006;81:65-7. (Pubitemid 43077216)
3. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005;365:1647-56. (Pubitemid 40703909)
4. Marsh JCW, Ball SE, Cavenagh J, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. Br J Haematol 2009;147:43-70.
5. Young NS, Shimamura A. Chapter 9: Acquired bone marrow failure syndromes. In: Handin RI, Lux SE, Stossel TP, eds. Blood: principles and practice of hematology. Philadelphia: Lippincott Williams & Wilkins, 2003:273-318.
6. Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011;365:430-8.
7. Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia. Cochrane Database Syst Rev 2013;7:CD006407.
8. The Cochrane Collaboration. 2.2.5 Publication of versions of Cochrane Reviews in print journals. The Cochrane Policy Manual [updated 12 July 2013]. Oxford: The Cochrane Collaboration, 2013.
9. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097-97.
10. Passweg JR, Marsh JCW. Aplastic Anemia: First-line treatment by immunosuppression and sibling marrow transplantation. Hematology Am Soc Hematol Educ Program 2010;2010:36-42.
11. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant 1991;7(Suppl 3):9-12.
12. Wheatley K, Gray R. Commentary: Mendelian randomization: an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol 2004;33:15-17. (Pubitemid 38500148)
13. Katan MB. Apolipoprotein E isoforms, serum cholesterol, and cancer. Lancet 1986;327:507-8. (Pubitemid 16138371)
14. EndNote [program]. New York: Thomson Reuters, 2013.
15. Higgins JPT, Altman DG, Sterne JAC. Table 8.5.a The Cochrane Collaboration's tool for assessing risk of bias. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 510 [updated March 2011]. The Cochrane Collaboration, 2011. http://wwwcochrane-handbookorg
16. Higgins JPT, Altman DG, Sterne JAC. Table 8.5.d Criteria for judging risk of bias in the 'Risk of bias' assessment tool. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane handbook for systematic reviews of interventions version 510 [updated March 2011]. The Cochrane Collaboration, 2011. http://wwwcochrane-handbookorg
17. Review Manager (RevMan) [program]. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
18. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-34. (Pubitemid 28562978)
19. Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
20. Bayever E, Champlin R, Ho W, et al. Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr 1984;105:920-5. (Pubitemid 15185319)
21. Gratwohl A, Osterwalder B, Nissen C, et al. Treatment of severe aplastic anemia. Schweiz Med Wochenschr 1981;111:1520-2. (Pubitemid 11018336)
22. Führer M, Burdach S, Ebell W, et al. Relapse and clonal disease in children with aplastic anemia (AA) after immunosuppressive therapy (IST): the SAA 94 experience. Klin Padiatr 1998;210:173-9. (Pubitemid 28361236)
23. Führer M, Rampf U, Baumann I, et al. Immunosuppressive therapy for aplastic anemia in children: a more severe disease predicts better survival. Blood 2005;106:2102-4. (Pubitemid 41291726)
24. Führer M, Bender-Götze C, Ebell W, et al. Treatment of aplastic anemia - aims and development of the SAA 94 pilot protocol. Klin Padiatr 1994;206:289-95. (Pubitemid 24248166)
25. Führer M, Rampf U, Burdach S. Immunosuppressive therapy (IST) and bone marrow transplantation (BMT) for aplastic anemia (AA) in children. Blood 1998;92:156a, abstract 631-156a, abstract 631.
26. Führer M, Rampf U, Niemeyer CM, et al. Bone marrow transplantation and immunosuppressive therapy in children with aplastic anemia: data from a prospective multinational trial in Germany, Austria and Switzerland. Blood 2004;104:abstract 1439-abstract 39.
27. Guinan EC. Acquired aplastic anemia in childhood. Hematol Oncol Clin North Am 2009;23:171-91.
28. Sangiolo D, Storb R, Deeg HJ, et al. Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. Biol Blood Marrow Transplant 2010;16:1411-18.
29. Bacigalupo A. Treatment strategies for patients with severe aplastic anemia. Bone Marrow Transplant 2008;42(Suppl 1):S42-4.
30. Peinemann F, Grouven U, Kroger N, et al. First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS ONE 2011;6:e18572-72.
31. Kojima S, Nakao S, Young N, et al. The Third Consensus Conference on the treatment of aplastic anemia. Int J Hematol 2011;93:832-7.
32. Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. Hematology Am Soc Hematol Educ Program 2012;2012:292-300.
33. Nitsch D, Molokhia M, Smeeth L, et al. Limits to causal inference based on Mendelian randomization: a comparison with randomized controlled trials. Am J Epidemiol 2006;163:397-403.